Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

SNSS 2.24 +0.12 (5.66%)
price chart
Sunesis Pharmaceuticals Bounces On Results Announcement
Sunesis Pharmaceuticals, Inc. (SNSS) jumped +51.2% early in the day following the announcement that the company will reveal the results of one of its late-stage drug trials in December.
Related articles »  
Ahead of the Bell: Sunesis Pharma shares sink
Sunesis said it will seek marketing approval from European regulators and also will meet with the U.S. Food and Drug Administration to determine the "appropriate regulatory path forward.
An Insight Into Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)  Inside Trade
Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin ...  MarketWatch
Related articles »  
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3%
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) was a big mover last session with its shares surging over 38% on the day.
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape  Nasdaq
Related articles »  
Is This the Sunesis Resurrection?
In early October, Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) announced that its Phase 3 clinical trial of vosaroxin and cytarabine failed to meet the primary endpoint of the study, which ultimately had catastrophic results for the stock price ...
Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 ...
Sunesis Pharmaceuticals, Inc. SNSS, +38.32% today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) will be presented in a late-breaking oral ...
Focus on Healthcare Stocks- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) [Detail Analytic Report] currently declared that the online publication of outcomes from the firm's segment 1b/2 research of vosaroxin in amalgamation with cytarabine in patients with declined or intractable ...
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and ...
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended September 30, 2014.
Related articles »  
Three Stocks To Watch: Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS), Cache ...
This article discusses three companies:Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS), Cache Inc(NASDAQ:CACH) and Cincinnati Bell Inc.(NYSE:CBB).
Biotech Stocks Jump On Some Enormous News: Sunesis Pharmaceuticals, Inc ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) soared 38.32% yesterday after the company declared that results from the company's phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia will be ...
Could Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS), Resolute Energy Corp ...
Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS) is a California-based biopharmaceutical company that develops and commercializes oncology therapeutics for the treatment of both solid and hematologic cancers.
Stocks to Keep Your Eyes on - Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS ...  Techsonian (press release)
Morning Buzz: MannKind Corp. (NASDAQ:MNKD), Sunesis Pharmaceuticals ...  Gaining Green
Related articles »